Autism Spectrum Disorder Trial, Recruiting NCT06477263 Sponsor: Neurocytonix, Inc. Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06477263
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a confirmed diagnosis of Autism Spectrum Disorder (ASD) based on standard diagnostic guidelines (DSM-5).
  • You are between 3 and 50 years old (inclusive).
  • Your ASD has been assessed as any severity level (mild, moderate, or severe) according to standard diagnostic guidelines.
  • A parent or legal guardian has given written permission for your participation (required for those who cannot consent for themselves).
  • You are physically able and willing to attend and take part in the treatment sessions.
  • You are in a stable enough state of physical and mental health to take part in the study.

Who may not be able to join:

  • You have a serious medical condition that could make the treatment device unsafe to use, such as severe neurological disorders or epilepsy that is difficult to control (for example, having more than one major seizure per month in the past 3 months, or a history of very long seizures, repeated seizures requiring emergency medication more than once a month, seizures lasting over 10 minutes, or certain severe seizure episodes in the past 9 months — confirm details with trial site).
  • You are currently receiving other therapies or treatments specifically for autism at the same time as this trial.
  • You are unable to attend treatment sessions regularly due to practical or personal circumstances.
  • You have had significant bad reactions to similar treatments or to anesthesia in the past.
  • You have serious behavioral problems or a tendency toward aggression that could put yourself or staff members at risk during treatment sessions.
  • You have had a significant bacterial, fungal, viral, or other infection in the past 14 days.
  • You have a metal implant in your body, a pacemaker, severe claustrophobia (fear of enclosed spaces), or any other condition that would prevent you from safely entering or staying inside the treatment device.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: J R Trujillo, jrtrujillo@neurocytonix.com

Phone: +528135414706

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Neurocytonix, Inc.
Registry
ClinicalTrials.gov
Start date
15 July 2024
Est. completion
6 March 2025

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Changes in Autism Diagnostic Observation Schedule-Second Edition scale scores; Changes in Adaptive Behavioral Assessment System scores; Changes in Childhood Autism Rating Scale scores; Changes in Gilliam Autism Measurement Scale score; Withdrawal Rate; Adherence to Treatment; Treatment Security; Change in the number of seizures or epileptic seizures during the study period; Neurophysiological changes: in functional activity and brain anatomy using Magnetic Resonance Imaging; Neurophysiological changes: in functional activity and brain anatomy using Diffusion Tensor Imaging; Neurophysiological...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov